Chouraqui Jean Pierre, Grathwohl Dominik, Labaune Jean Marc, Hascoet Jean Michel, de Montgolfier Ines, Leclaire Michèle, Giarre Mariana, Steenhout Philippe
Gastroenterology and Nutrition Unit, Department of Pediatrics, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
Am J Clin Nutr. 2008 May;87(5):1365-73. doi: 10.1093/ajcn/87.5.1365.
Probiotics and prebiotics are considered to be beneficial to the gastrointestinal health of infants.
The objective was to evaluate infant formulas containing probiotics and synbiotics (combinations of probiotics and prebiotics) for safety and tolerance.
In a prospective, controlled, double-blind, randomized trial, healthy full-term infants were exclusively fed a control formula or study formulas containing Bifidobacterium longum BL999 (BL999) + Lactobacillus rhamnosus LPR (LPR), BL999 + LPR + 4 g/L of 90% galactooligosaccharide/10% short-chain fructooligosaccharide (GOS/SCFOS), or BL999 + Lactobacillus paracasei ST11 (ST11) + 4 g/L GOS/SCFOS from < or = 2 to 16 wk of age (treatment period). Safety and tolerance were assessed based on weight gain during the treatment period (primary outcome) as well as recumbent length, head circumference, digestive tolerance, and adverse events (secondary outcomes), which were evaluated at 2, 4, 8, 12, 16, and 52 wk of age.
Two hundred eighty-four infants were enrolled. During the treatment period, difference in mean weight gain between control and study formula groups in both the intention-to-treat and per-protocol populations were within the predefined equivalence boundaries of +/-3.9 g/d, indicating equivalent weight gain. Secondary outcomes did not show significant differences between groups during the treatment period.
Infants fed formulas containing probiotics or synbiotics show a similar rate in weight gain compared with those fed a control formula and tolerate these formulas well.
益生菌和益生元被认为有益于婴儿的胃肠道健康。
评估含益生菌和合生制剂(益生菌与益生元的组合)的婴儿配方奶粉的安全性和耐受性。
在一项前瞻性、对照、双盲、随机试验中,健康足月儿从2周龄至16周龄(治疗期)被纯母乳喂养对照配方奶粉或含长双歧杆菌BL999(BL999)+鼠李糖乳杆菌LPR(LPR)、BL999 + LPR + 4 g/L 90%低聚半乳糖/10%短链低聚果糖(GOS/SCFOS)或BL999 +副干酪乳杆菌ST11(ST11)+ 4 g/L GOS/SCFOS的研究配方奶粉。基于治疗期内的体重增加(主要结局)以及卧位身长、头围、消化耐受性和不良事件(次要结局)评估安全性和耐受性,这些指标在2、4、8、12、16和52周龄时进行评估。
共纳入284名婴儿。在治疗期内,在意向性分析人群和符合方案人群中,对照配方奶粉组与研究配方奶粉组的平均体重增加差异均在预先定义的等效界限±3.9 g/d内,表明体重增加相当。治疗期内各亚组间次要结局未显示出显著差异。
与喂养对照配方奶粉的婴儿相比,喂养含益生菌或合生制剂配方奶粉的婴儿体重增加率相似,且对这些配方奶粉耐受性良好。